Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 20 and 80 years old~* With multiple myeloma in 2nd or later relapse or showing resistance after 2 treatment lines~* Eastern Cooperative Oncology Group (ECOG) ≤ 2~* Life expectancy greater than six months~* Creatinine clearance rate more than 30 ml / min~* Subjects who have received at least 4 cycles of rescue treatment under the procedures of the 12 de Octubre Hospital (rescue treatment will vary depending on previous anti-myeloma treatment). After treatment, patients must have shown chemosensitivity and disease stabilization.~* Will be included subjects with partial response or stable disease (for at least 2 cycles) after 75% of planned rescue treatment or patients at subclinical progression (defined as an increase of monoclonal component ≥ 25%) at any time of rescue treatment. Subjects have to show tolerance to rescue treatment, without G3/4 adverse effects, if G1/2 adverse effects exist they must be analyzed immediately before starting reinfusion program.~* Subjects have to agree to participate in the trial and they have to sign informed consent.~Exclusion Criteria:~* Subjects with clinical progression or complete response will not be included.~* Any of the following abnormal laboratory results:~Absolute Neutrophil Count \< 1000/ µL Platelets Count \< 50000/ µL in those patients with bone marrow infiltration lower than 50% Measured creatinine clearance \<30 ml/min Hemoglobin level ≤ 8 g/dL Peripheral neuropathy ≥ Grade 2~* Subjects have received allogeneic stem cell transplant.~* Subjects with heart disease which compromises patient's life or protocol accomplishment.~* Subjects with past clinical history of malignant disease within 3 years (exceptions are squamous or basal cell carcinoma).~* Subjects receiving another investigational drug or having received investigational drug within 30 days before screening.~* Subjects who require chronic steroid or immunosuppressive treatment.~* Any condition, including abnormally laboratory results, that might compromise the patient´s life if he participate in this study.~* Any concurrent medical condition, abnormally laboratory results or any psychological disorder that prevent the patient to sign the informed consent.~* Pregnant or fertile women.~* Patients known to be seropositive for human immunodeficiency virus (VIH) or having active hepatitis A, B or C.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NKAE cells infusion + chemotherapy (Type: EXPERIMENTAL): Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).

Based on this trial design, predict the completion outcome and termination type (if applicable).